Drugs / fluticasone propionate/salmeterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00369993 | Mar → May 2005 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2017-07-21 | GlaxoSmithKline | Regulatory GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination gsk.com ↗ |
| 2016-03-06 | GlaxoSmithKline | Results NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma gsk.com ↗
This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations) and showed that Advair had a safety profile comparable to FP, including no asthma-related deaths in either arm. |
| 2012-01-09 | GlaxoSmithKline | Results GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma gsk.com ↗
A 4-week detailed lung function profile study in 54 patients demonstrated that all doses of FF/VI (50/25mcg, 100/25mcg, and 200/25mcg) statistically significantly increased weighted mean FEV1 versus placebo. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-07-21 | GlaxoSmithKline | GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination gsk.com ↗ |
| 2016-03-06 | GlaxoSmithKline | NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma gsk.com ↗ |
| 2012-01-09 | GlaxoSmithKline | GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma gsk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluticasone propionate/salmeterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00369993 ↗ |
| Route | Inhaled | “fluticasone propionate and salmeterol from SERETIDE™/ADVAIR™ 250 HFA MDI” NCT00369993 ↗ |